Pilot Study of Ixazomib to Reduce the Number of HIV DNA Positive Lymphoid Cells

Trial Profile

Pilot Study of Ixazomib to Reduce the Number of HIV DNA Positive Lymphoid Cells

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Ixazomib (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Mar 2017 Planned End Date changed from 1 Sep 2019 to 1 Sep 2020.
    • 21 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 03 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top